Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director | February 28, 2020 | May 01, 2020 |
| BioAge Labs, Inc.BIOA · Entity 5569 | Chief Financial Officer | April 23, 2026 | April 24, 2026 |
| Coya Therapeutics, Inc.COYA · Entity 6727 | Director | January 02, 2026 | January 07, 2026 |
| Esperion Therapeutics, Inc.ESPR · Entity 30796 | Director | June 06, 2018 | June 08, 2018 |
| Gain Therapeutics, Inc.GANX · Entity 6943 | Director | July 15, 2026 | July 17, 2026 |
| MELINTA THERAPEUTICS, INC. /NEW/CEMP · Entity 154249 | Director | March 07, 2017 | March 09, 2017 |
| NeuBase Therapeutics, Inc.NBSE · Entity 109568 | Director | September 09, 2022 | September 12, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date February 28, 2020 · Filed May 01, 2020 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,500 |
Reported balance
After 2020-02-28 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2020-02-28 · Grant · Acquired 7,500 · Balance 7,500 F1: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.
BioAge Labs, Inc.
Report date April 23, 2026 · Filed April 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,575 |
Reported balance
After 2026-04-23 transaction · row 1
1 source rowRow 1 · 2026-04-23 · Exercise / conversion · Acquired 3,542 · Balance 36,575 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.38 · Expires 2035-02-17 | Direct | 155,833 |
Reported balance
After 2026-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-23 · Exercise / conversion · Disposed 3,542 · Balance 155,833 F1: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Coya Therapeutics, Inc.
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.65 · Expires 2036-01-02 | Direct | 10,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 10,000 · Balance 10,000 F1: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continuous service, 100% of the option will vest on the first anniversary of the date of grant.
Esperion Therapeutics, Inc.
Report date June 06, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47 |
Ending reported balance
After 2018-06-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-06-06 · Exercise / conversion · Acquired 5,000 · Balance 5,047 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Row 2 · 2018-06-06 · Exercise / conversion · Acquired 8,000 · Balance 13,047 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Row 3 · 2018-06-06 · Other · Disposed 5,000 · Balance 8,047 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Row 4 · 2018-06-06 · Other · Disposed 8,000 · Balance 47 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.42 · Expires 2024-05-15 | Direct | 0 |
Reported balance
After 2018-06-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-06 · Exercise / conversion · Acquired 5,000 · Balance 0 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.75 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2018-06-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-06-06 · Exercise / conversion · Acquired 8,000 · Balance 0 F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein.
Gain Therapeutics, Inc.
Report date July 15, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.68 · Expires 2036-07-15 | Direct | 25,000 |
Reported balance
After 2026-07-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-15 · Grant · Acquired 25,000 · Balance 25,000 F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in 12 equal monthly installments commencing on July 24, 2026, subject to the Reporting Person's continuous service through the applicable vesting date.
MELINTA THERAPEUTICS, INC. /NEW/
Report date March 07, 2017 · Filed March 09, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Aisling Capital II, LP | 0 |
Last balance in matching sequence
After 2017-03-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-03-07 · Sale · Disposed 50,100 · Balance 99,900 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F3: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Row 2 · 2017-03-08 · Sale · Disposed 99,900 · Balance 0 F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 95 |
Reported balance
Holding disclosure · report date 2017-03-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 95 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
NeuBase Therapeutics, Inc.
Report date September 09, 2022 · Filed September 12, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2032-09-09 | Direct | 37,600 |
Reported balance
After 2022-09-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-09 · Grant · Acquired 37,600 · Balance 37,600 F1: 25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2017 Filed Dec 20, 2017 22:53 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Exercise / conversionCommon Stock | 21,471 | $3.70 | $79,442.70 |
DisclosureSEC source: 0001179110-17-015732 · edgar.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,518 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reporting person was formerly a managing partner at Aisling Capital, which is an affiliate of Aisling Capital II, L.P. ("Aisling"). Under the partnership agreement for the Aisling, the reporting person was deemed to hold the stock option and the shares issuable thereunder for the benefit of Aisling. The stock option was exercised at the direction of Aisling and the shares issued upon exercise were delivered to Aisling. The reporting person disclaims beneficial ownership of the stock option and the shares issuable thereunder, except to the extent of his pecuniary interest therein. Read SEC document |
| December 05, 2017 Filed Dec 8, 2017 21:42 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | OtherCommon Stock | 38 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-015123 · edgar.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47 F1 · kind: Pro rata distribution from Aisling Capital II LP Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:01 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 53,837 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001054 · e616261_4-goldstein.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,837 Underlying: Common Stock · 53,837 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 7, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| April 17, 2017 Filed Apr 20, 2017 01:00 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 14,000 | $0.00 Strike: $38.96 | $0.00 |
DisclosureSEC source: 0000950142-17-000823 · es1700532_4-goldstein.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2027-04-17 F1 · derivative.exercise_date: The options vest in full on the earlier of (i) April 17, 2018 and (ii) the Issuer's next annual meeting of stockholders following April 17, 2017. Read SEC document |
| March 22, 2017 Filed Mar 23, 2017 20:37 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 312,642 | $38.82 | $12,136,762.44 |
DisclosureSEC source: 0000950142-17-000629 · es1700432_4-goldstein.xml · nonDerivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital II, LP Disclosed balance after: 837,125 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.75 to $41.29, inclusive. F2 · ownership.nature: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| March 21, 2017 Filed Mar 23, 2017 20:37 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | SaleCommon Stock | 487,358 | $43.48 | $21,190,325.84 |
DisclosureSEC source: 0000950142-17-000629 · es1700432_4-goldstein.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital II, LP Disclosed balance after: 1,149,767 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $46.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. F2 · ownership.nature: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| March 08, 2017 Filed Mar 9, 2017 18:21 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | SaleCommon Stock | 99,900 | $3.57 | $356,443.20 |
DisclosureSEC source: 0000950142-17-000550 · es1700390_4-goldstein.xml · nonDerivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital II, LP Disclosed balance after: 0 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 18:21 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | SaleCommon Stock | 50,100 | $3.53 | $176,672.64 |
DisclosureSEC source: 0000950142-17-000550 · es1700390_4-goldstein.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital II, LP Disclosed balance after: 99,900 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.500 to $3.575, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F3 · ownership.nature: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:14 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000280 · e615793_4-goldstein.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| January 13, 2017 Filed Jan 18, 2017 21:17 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | SaleCommon Stock | 105,460 | $3.40 | $358,564.00 |
DisclosureSEC source: 0000950142-17-000120 · es1700187_4-goldstein.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital II, LP Disclosed balance after: 150,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.40 to $3.425, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · ownership.nature: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| January 06, 2017 Filed Jan 6, 2017 22:24 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | SaleCommon Stock | 437,600 | $3.64 | $1,592,864.00 |
DisclosureSEC source: 0000950142-17-000081 · es1700159_4-goldstein.xml · nonDerivative · entry 2 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital II, LP Disclosed balance after: 255,460 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $3.75, inclusive. F2 · ownership.nature: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 22:24 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | SaleCommon Stock | 500,000 | $3.20 | $1,600,000.00 |
DisclosureSEC source: 0000950142-17-000081 · es1700159_4-goldstein.xml · nonDerivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Aisling Capital II, LP Disclosed balance after: 693,060 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.23, inclusive. The reporting person undertakes to provide to Cempra, Inc., any security holder of Cempra, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. F2 · ownership.nature: The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC, as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
| January 03, 2017 Filed Feb 16, 2017 21:19 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0000950142-17-000381 · es1700309_4-goldstein.xml · derivative · entry 1 GOLDSTEIN DOV A MD · CIK 0001120478 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-01-02 F1 · derivative.exercise_date: The option vests according to the following schedule: 1/12th of the shares vest at the end of each month over 12 months, beginning January 1, 2017. F2 · ownership.direct: These stock options are held by Dr. Goldstein for the benefit of Aisling Capital LLC. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.